Breast Cancer
Conditions
Interventions
HR+HER2-breast cancer group:None
HER2+ breast cancer group:None
Triple-negative breast cancer group:None
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Signed an informed consent. 2.Age >= 18 years. 3.Female. 4.Histologically confirmed diagnosis of unilateral invasive breast cancer. 5.Molecular subtype must be confirmed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Exclusion criteria
Exclusion criteria: 1.Presence of distant metastases. 2.History of another malignant disease, except for appropriately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancers from which the patient has been disease-free for over 5 years. 3.Prior antitumor therapy before participating in this study. 4.Did not receive curative breast cancer surgery following neoadjuvant therapy. 5.No pathological diagnosis was performed on the curative surgery specimen. 6.Immunodeficiency or HIV infection. 7.Severe impairment of cardiac, pulmonary, hepatic, or renal function. 8.Uncontrolled or active infection. 9.Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Complete Response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Miller-Payne Grading;Residual Cancer Burden Grading;Event-free Survival;Overall Survival; | — |
Countries
China
Contacts
Public ContactZhimin Shao
Fudan University Shanghai Cancer Center
Outcome results
None listed